In 2017, we received funding from CIHR’s Partnership for Health Systems Improvement  initiative for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) collaboration. This collaboration will develop a framework for the generation and use of Real World Evidence (RWE) for cancer drug funding decisions in Canada.

The CanREValue collaboration brings together key stakeholders including ARCC, CADTH/ pCODR, CAPCA, Health Canada, INESSS, Ministries/departments of Health, pCPA, and provincial cancer agencies from across Canada. By providing a platform for stakeholders to discuss their needs and existing evidence gaps, the CanREValue collaboration will enable knowledge exchange,  and address policy relevant research questions.

Contact us:  CanREValue@cc-arcc.ca